Trillium(TM) biopassive surface: A new biocompatible treatment for extracorporeal circulation circuits

A. Cazzaniga, M. Ranucci, G. Isgrò, G. Soro, D. De Benedetti, R. Corradi, M. Gardinali

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

139 patients undergoing cardiac surgery were included in a prospective, randomized trial. Patients were randomly allocated to receive cardiopulmonary bypass (CPB) with Trillium(TM) Biopassive Surface (TBS Group) coated oxygenators or conventional circuits (control group). 112 patients were studied with respect to postoperative biochemical profile; a subgroup of 27 patients was studied with respect to perioperative complement (C3a) activation. Patients in the TBS group demonstrated a significantly lower white blood cell count at the end of the operation (p=0.036) and a significantly higher platelet count the day after the operation (p=0.023) when compared to the control group. C3a was significantly higher (p=0.02) in the TBS group after 30 minutes of CPB, but the C3a increase after protamine administration was significantly less pronounced in the TBS group vs. the control group. Further studies involving platelet and leukocyte activation are required to better elucidate the action of this new coating in the setting of routine CPB.

Original languageEnglish
Pages (from-to)319-324
Number of pages6
JournalInternational Journal of Artificial Organs
Volume23
Issue number5
Publication statusPublished - May 2000

Fingerprint

Trillium
Extracorporeal Circulation
Platelets
Cardiopulmonary Bypass
Networks (circuits)
Complement C3a
Chemical activation
Oxygenators
Protamines
Control Groups
Surgery
Blood
Therapeutics
Cells
Complement Activation
Platelet Activation
Coatings
Platelet Count
Leukocyte Count
Thoracic Surgery

Keywords

  • Biocompatible materials
  • Cardiopulmonary bypass
  • Complement activation

ASJC Scopus subject areas

  • Biophysics

Cite this

Cazzaniga, A., Ranucci, M., Isgrò, G., Soro, G., De Benedetti, D., Corradi, R., & Gardinali, M. (2000). Trillium(TM) biopassive surface: A new biocompatible treatment for extracorporeal circulation circuits. International Journal of Artificial Organs, 23(5), 319-324.

Trillium(TM) biopassive surface : A new biocompatible treatment for extracorporeal circulation circuits. / Cazzaniga, A.; Ranucci, M.; Isgrò, G.; Soro, G.; De Benedetti, D.; Corradi, R.; Gardinali, M.

In: International Journal of Artificial Organs, Vol. 23, No. 5, 05.2000, p. 319-324.

Research output: Contribution to journalArticle

Cazzaniga, A, Ranucci, M, Isgrò, G, Soro, G, De Benedetti, D, Corradi, R & Gardinali, M 2000, 'Trillium(TM) biopassive surface: A new biocompatible treatment for extracorporeal circulation circuits', International Journal of Artificial Organs, vol. 23, no. 5, pp. 319-324.
Cazzaniga, A. ; Ranucci, M. ; Isgrò, G. ; Soro, G. ; De Benedetti, D. ; Corradi, R. ; Gardinali, M. / Trillium(TM) biopassive surface : A new biocompatible treatment for extracorporeal circulation circuits. In: International Journal of Artificial Organs. 2000 ; Vol. 23, No. 5. pp. 319-324.
@article{1f373d562890429680b5721208ce6591,
title = "Trillium(TM) biopassive surface: A new biocompatible treatment for extracorporeal circulation circuits",
abstract = "139 patients undergoing cardiac surgery were included in a prospective, randomized trial. Patients were randomly allocated to receive cardiopulmonary bypass (CPB) with Trillium(TM) Biopassive Surface (TBS Group) coated oxygenators or conventional circuits (control group). 112 patients were studied with respect to postoperative biochemical profile; a subgroup of 27 patients was studied with respect to perioperative complement (C3a) activation. Patients in the TBS group demonstrated a significantly lower white blood cell count at the end of the operation (p=0.036) and a significantly higher platelet count the day after the operation (p=0.023) when compared to the control group. C3a was significantly higher (p=0.02) in the TBS group after 30 minutes of CPB, but the C3a increase after protamine administration was significantly less pronounced in the TBS group vs. the control group. Further studies involving platelet and leukocyte activation are required to better elucidate the action of this new coating in the setting of routine CPB.",
keywords = "Biocompatible materials, Cardiopulmonary bypass, Complement activation",
author = "A. Cazzaniga and M. Ranucci and G. Isgr{\`o} and G. Soro and {De Benedetti}, D. and R. Corradi and M. Gardinali",
year = "2000",
month = "5",
language = "English",
volume = "23",
pages = "319--324",
journal = "International Journal of Artificial Organs",
issn = "0391-3988",
publisher = "Wichtig Publishing",
number = "5",

}

TY - JOUR

T1 - Trillium(TM) biopassive surface

T2 - A new biocompatible treatment for extracorporeal circulation circuits

AU - Cazzaniga, A.

AU - Ranucci, M.

AU - Isgrò, G.

AU - Soro, G.

AU - De Benedetti, D.

AU - Corradi, R.

AU - Gardinali, M.

PY - 2000/5

Y1 - 2000/5

N2 - 139 patients undergoing cardiac surgery were included in a prospective, randomized trial. Patients were randomly allocated to receive cardiopulmonary bypass (CPB) with Trillium(TM) Biopassive Surface (TBS Group) coated oxygenators or conventional circuits (control group). 112 patients were studied with respect to postoperative biochemical profile; a subgroup of 27 patients was studied with respect to perioperative complement (C3a) activation. Patients in the TBS group demonstrated a significantly lower white blood cell count at the end of the operation (p=0.036) and a significantly higher platelet count the day after the operation (p=0.023) when compared to the control group. C3a was significantly higher (p=0.02) in the TBS group after 30 minutes of CPB, but the C3a increase after protamine administration was significantly less pronounced in the TBS group vs. the control group. Further studies involving platelet and leukocyte activation are required to better elucidate the action of this new coating in the setting of routine CPB.

AB - 139 patients undergoing cardiac surgery were included in a prospective, randomized trial. Patients were randomly allocated to receive cardiopulmonary bypass (CPB) with Trillium(TM) Biopassive Surface (TBS Group) coated oxygenators or conventional circuits (control group). 112 patients were studied with respect to postoperative biochemical profile; a subgroup of 27 patients was studied with respect to perioperative complement (C3a) activation. Patients in the TBS group demonstrated a significantly lower white blood cell count at the end of the operation (p=0.036) and a significantly higher platelet count the day after the operation (p=0.023) when compared to the control group. C3a was significantly higher (p=0.02) in the TBS group after 30 minutes of CPB, but the C3a increase after protamine administration was significantly less pronounced in the TBS group vs. the control group. Further studies involving platelet and leukocyte activation are required to better elucidate the action of this new coating in the setting of routine CPB.

KW - Biocompatible materials

KW - Cardiopulmonary bypass

KW - Complement activation

UR - http://www.scopus.com/inward/record.url?scp=0033623890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033623890&partnerID=8YFLogxK

M3 - Article

C2 - 10872850

AN - SCOPUS:0033623890

VL - 23

SP - 319

EP - 324

JO - International Journal of Artificial Organs

JF - International Journal of Artificial Organs

SN - 0391-3988

IS - 5

ER -